A historical review of hemostasis, thrombosis, and antithrombotic therapy

Annals of Plastic Surgery

Volumn 39, Issue 3, 1997, Pages 317-329

  Stassen, Jean Marie ^a   Nyström, Åke ^a,b,c  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

BLOOD CLOT LYSIS; BLOOD CLOTTING; ENDOTHELIUM CELL; FIBRINOLYSIS; HEMOSTASIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEMATOLOGIC AGENTS; HEMOSTASIS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0030763273     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000637-199709000-00017     Document Type: Review

References (142)

1. Vlastou C, Earle AS. Beyond replantation: microsurgical salvage of complex hand injuries. Orihop Rev 1987;16:739-746
2. Schnltze M. Ein heizbarer Objecttisch und seine Ver- Wendung bei Untersuchungen des Blutes. Arch Mikroskop Anat 1865;1:1-42
3. Bizzozero J. Uber einem neuen Formbestandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnerung. Virchows Arch Pathol Anat Histopathol 1882;90:261-332
4. Grunert BK, et al. Classification system for factitious syndromes in the hand with implications for treatment. J Hand Surg [Am] 1991;16:1027-1030
5. Pytela R, et al. Platelet membrane glycoprotein II/IIIa: member of a family of Arg-Gly-Asp - specific adhesion receptors. Science 1986;231:1559-1562
6. Plow EF, et al. Immunologic relationship between platelet membrane glycoprotein GPIIb/IIIa and cell surface molecules expressed by a variety of cells. Proc Natl Acad Sci USA 1986;83:6002-6006
7. Chiang TM, Kaog AH. Isolation and purification of collagen alphal(I) receptor from human platelet membrane. J Biol Chem 1982;257:7581-7586
8. Gross M, Greenber LA. The salicylates: a critical bibliographic review. New Haven, CT: Hillhouse Press, 1948:1-8
9. Craven LL. Acetylsalicylic acid, a possible preventive of coronary thrombosis. Ann West Med Surg 1950;4:95
10. Gibson PC. Salicylic acid for coronary thrombosis. Lancet 1948;i:965 [letter]
11. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956;78:213-215
12. O'Brien JR. Effects of salicylates on human platelets. Lancet 1968;i:779-783
13. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-235
14. Fuster V, Jang IK. Role of platelet-inhibitor agents in coronary artery disease. In: Topol EJ, ed. Textbook of interventional cardiology. Philadelphia: WB Saunders, 1994:3-22
15. ISIS-2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Second International Study of Infarct Survival Collaborative Group. Lancet 1988;ii:349-360
16. Hennekens CH, et al. An overview of the British and American aspirin studies. N Engl J Med 1988;318:923-924 [letter]
17. Food and Drug Administration. Aspirin for heart patients. FDA Drug Bull 1985;15:34
18. Peto R, et al. Randomised trial of prophylactic daily aspirin in British male doctors, Br Med J Clin Res Ed 1988;296:313-316
19. Hewson W. An experimental inquiry into the properties of blood. London: Cadell, 1771
20. Hammarsten O. Zur Lehre von der Faserstoffgerinnung. Pflugers Arch Gesamte Physiol Menschen Tiere 1877;14:211-273
21. Peckelharing CA. Verhandeling der Koninklijke Akademie van Wetenschappen. Sectie 2 deel 1. Amsterdam: 1892
22. Napoleon A. The presentation of personalities in plastic surgery. Ann Plast Surg 1993;31:286-287
23. Pavlov IP. Biokhimya Svonttyvaniya Krovi. Kiev: 1957
24. Morawitz P. Die Chemie der Blutgerinnung 1905. Ergeb Physiol 1905;307
25. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1210
26. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964;202:498
27. Broze GJ. Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trends Cardiovasc Med 1992;2:72-77
28. Howell WH. The coagulation of blood. Harvey Lect 1916;12:272-323
29. Howell WH. Two new factors in blood coagulation: heparin and pro-antithrombin. Am J Physiol 1918;47:328-334
30. Baylis WM. Principles of general physiology. New York: Longman and Green, 1915:703
31. Bettman OL. A pictorial history of medicine. Springfield, IL: CC Thomas, 1972
32. Murray DWG, Jaques LB, Best CH. Heparin and vascular occlusion. Can Med Assoc J 1936;35:621-635
33. Hedenius P, Wilander O. The influence of intravenous injections of heparin in man on the time of coagulation. Acta Med Scand 1936;88:443
34. Brinkhous KM, et al. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin. Am J Physiol 1939;125:683-687
35. Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968;21:89-91
36. Fink E. Comparison of hirudins. Semin Thromb Hemost 1989;15:283-287
37. FitzGerald GA, Shipp E. Antiplatelet and anticoagulant drugs in coronary vascular disease. Ann Epidemiol 1992:2:529-542
38. Bang NU, Clayman MD. Antithrombotic agents from salivary glands of hematophagous animals. Trends Cardiovasc Med 1992;2:183-188
39. Haycraft JB. Ueber die Einwerkung eines Skretes des oflicinellen Blutegels auf die Gerinnbarkeit des Blutes. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol 1884;18:209-217
40. Jacoby C. Dtsch Med Wochenschr 1904;30:1786
41. Homeister JW, et al. Recombinant hirudin reduces the incidence of thrombotic occlusion in a canine model of coronary vascular injury. Coron Artery Dis 1991;2:237-246
42. Sarembock IJ, et al. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991;84:232-243
43. Imura Y, Stassen JM, Collen D. Comparative antithrombotic effects of hoparin. recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 1992;261:895-898
44. Zoldhelyi P, et al. Recombinanl hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993;88:2015-2022
45. Kelly AB, et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991;77:1006-1012
46. Neuhaus KL, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-1642
47. Munro R, Jones CP, Sawyer RT. Calin - a platelet adhesion inhibitor from the saliva of the medicinal leech. Blood Coagul Fibrinolysis 1991;2:179-184
48. Harsfalvi J. et al. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood 1995;85:705-711
49. Deckinyn H, et al. Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. Blood 1995;85:712-719
50. Smith JB, Dangelmaier C, Selak M. Identification of 50 kDa snake venom proteins which specifically inhibit platelet adhesion to collagen. FEBS Lett 1991;283:307-310
51. Connolly TM, Jacobs JW, Condra C. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalix leech. I. Identification, isolation, and characterization. J Biol Chem 1992;267:6893-6898
52. Koller PM, et al. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. II. Cloning of the cDNA and expression. J Biol Chem 1992;267:6899-6904
53. Waxman L, Connolly TM. Isolation of an inhibitor selective for collagen-stimulated platelet aggregation from the soft tick Ornithodoros moubata. J Biol Chem 1993;268:5445-5449
54. Keller PM, et al. Cloning of the cDNA and expression of moubatin, an inhibitor of platelet aggregation. J Biol Chem 1993;268:5450-5456
55. Noeske-Jungblut C, et al. Collagen-induced platelet aggregation is specifically inhibited by a salivary protein of the assassin bug (Triatoma pallidipennis). Thromb Haemost 1993;69:783 [abstract]
56. Schafer LW, et al. Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons. Arterioscler Thromb 1993;13:1593-1601
57. Schofield FW. Hemorraghic sweet clover disease in cattle. Can Vet Rec 1922;3:74-75
58. Roderick LM. Problems in the coagulation of blood: "sweet clover disease of cattle." Am J Physiol 1931;96:413-425
59. Link KP. The anticoagulant from spoiled sweet clover hay. Harvey Lect 1943;34:162-207
60. Link KP. The discovery of the coumarins and its sequels. Circulation 1959;19:97-107
61. Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935;190:501-511
62. Stenflo J, et al. Vitamin K dependent modifications of glulamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974;71:2730-2733
63. von Brucke E. Die verdauende Substanz im Urin. Sb Akad Wiss (Vienna) 1861;43:601-615
64. Dastre A. Fibrinolyse dans le sang. Arch Norn Pathol 1693;6:661-663
65. Tillet WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485-502
66. Christensen LR, MacLeod M. A proteolytic enzyme of serum: characterization, activation and reaction with inhibitors. J Gen Physiol 1945;28:363-383
67. Kaplan MH. Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med 1944;57:40-43
68. Sherry S. The origin of thrombolytic therapy. J Am Coll Cardiol 1989;14:1085-1092
69. Johnson AJ, McCarthy WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest 1959;38:1627-1643
70. Fletcher AP, et al. Development of urokinase as a thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965;656:713-731
71. Astrup T, Permin PM. Fibrinolysis in animal organisms. Nature 1947;159:681-682
72. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981;256:7035-7041
73. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinaso in rabbits with experimental pulmonary embolus. Nature 1981;291:590-591
74. Weimar W, et al. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981;ii:1018-1020
75. Ponnica D, et al. Cloning and expression of human tissue-type, plasminogen activator cDNA in E. coli. Nature 1983;301:214-221
76. Collen D, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984;70:1012-1017
77. Virchow R. Phlogose und Thrombose in Gefassystem. In: Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt-am-Main: Meidinger Sohn and Company. 1856:458-463
78. Grimbrone MAJ. Culture of vascular endothelium. In: Spaet TH, ed. Progress in hemostasis and thrombosis. New York: Grune and Stratton, 1976:1-28
79. Fishman AP. Endothelium: a distributed organ of diverse capabilities. Ann N Y Acad Sci 1982;401:1-8
80. Grimbrone MAJ. Vascular endothelium in thrombosis and haemostasis. Edinburgh: Churchhill Livingstone, 1986
81. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-373
82. Woolf N, Davies MJ. Interrelationship between atherosclerosis and thrombosis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992:41-77
83. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet, adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 1978;279:636-638
84. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992:1-16
85. Clement DL, Verhaeghe R. Atherosclerosis and other occlusive arterial diseases. In: Clement DL, Shepherd JT, eds. Vascular diseases in the limbs. Mechanisms and principles of treatment. St. Louis: Mosby, 1993:71-89
86. de Groot PG, Sixma JJ. Platelet adhesion. Br J Haematol 1990;75:308-312
87. Dupe RJ, et al. Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism. Thromb Haemost 1984;51:248-253
88. Ruggeri ZM. Functional domains of von Willebrand factor involved in interactions with platelets and the subendothelium. In: Platelet membrane receptors: molecular biology, immunology, biochemistry, and pathology. Alan R. Liss, 1988:219-253
89. Ruoshlathi E. Integrins. J Clin Invest 1991;87:1-5
90. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haomost 1988;59:1-6
91. Peerschke EIB. The platelet flbrinogen receptor. Semin Hematol 1985;22:241-259
92. Zwaal RFA. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978;515:163-205
93. Bach RR. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988;23:339-368
94. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-1097
95. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74:5260-5264
96. Zur M, Nemerson Y. The esterase activity of coagulation factor VII. Evidence for intrinsic activity of the zymogen. J Biol Chem 1978;253:2203-2209
97. Mann KG, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990;76:1-16
98. Zwaal RFA, Bevors EM, Comfurius P. Platelets and coagulation. In: Zwaal RFA. Hemker HC, eds. Blood coagulation. New York: Elsevier Science Publishers, 1986:141-169
99. Mann KG, Nesheim ME, Fraey PB. Nonenzymatic cofactors: factor V. In: Zwaal RFA. Hemker HC, eds. Blood coagulation. New York: Elsevier Science Publishers, 1986:15-32
100. Alpert BS, Buncke HJ. Brownstein M. Replacement of damaged arteries and veins with vein grafts when replanting crushed, amputated fingers. Plast Reconstr Surg 1978;61:17-22
101. Collen D, Lijnen HR, Verstraete M. Fibrinolytic system and its disorders. In: Handin RI, Lux SE, Stossel TP, eds. Blood: principles and practice of hematology. Philadelphia: JB Lippincott. 1995:1261-1288
102. Wiman B, Collon D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J Biol Chem 1979;254:9291-9297
103. Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma. Blood 1978;51:563-569
104. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978;272:549-550
105. Collen D, Lijuen HR. Molecular and cellular basis of Obrinolysis: In: Huffman R, Benz EJ, Shattil SJ, et al, ods. Homatology: basic principles and practice. Now York: Churchill Livingstone, 1991;1232-1242
106. American Heart Association. Heart and stroke facts: statistical supplement. 1995
107. Barrowcliffe TW, Thomas DP, van den Besselaar AMHP, et al. eds. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1994;1415-1477
108. Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol Rev 1993;42:201-222
109. Lijnen HR, Collen D. Development of thrombolytic agents. Biotechnol Adv 1993;11:115-130
110. van den Besselaar AMHP. Oral anticoagulant therapy. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haomostasis and thrombosis. Edinburgh: Churchill Livingstone, 1994:1439-1457
111. Schaffor LW, et al. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991;84:1741-1748
112. Zoldhelyi P, Fuster V, Chesebro JH. Antithrombins as conjunctive therapy in arterial thrombolysis. Coron Artery Dis 1992;3:1003-1009
113. Weitz JI, et al. Clot-hound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391
114. Théroux P, Lidon R. Anticoagulants and their use in acute ischemic syndrome. In: Topol EJ, ed. Textbook of interventional cardiology. Philadelphia: WB Saunders, 1994:23-45
115. Beretz A, Cazenave JP, Old and new natural products as the source of modern antithrombotic drugs. Planta Med 1991;57:S68-S72
116. Jacobs JW, et al. Isolation and characterization of a coagulation factor Xa inhibitor from black fly salivary glands. Thromb Haemost 1990;64:235-238
117. Eisenberg PR. Development of novel anticoagulants for use as conjunctive therapy for thrombolysis. Coron Artery Dis 1992;3:1010-1015
118. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-3124
119. Collen D, Lijnen HR. Thrombolytic therapy. Ann NY Acad Sci 1991;614:259-269
120. Verhaeghe R, Verstraete M. Hemostasis, thrombosis, and antithrombotic and thrombolytic therapy. In: Clement DL, Shepherd JT, eds. Vascular diseases in the limbs. Mechanisms and principles of treatment. St. Louis: Mosby, 1993:133-152
121. Verhaeghe R, Bounameaux H. Peripheral arterial occlusion: thromboembolism and antithrombotic therapy. In: Fustor V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992:423-449
122. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983;71:368-376
123. Collen D, et al. Biological properties of human tissuetype plasminogen activator obtained by expression of recombinant DMA in mammalian cells. J Pharmacol Exp Ther 1984;231:146-152
124. Stassen JM, et al. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemost 1987;58:947-950
125. The GUSTO angiographic investigators. The effects of tissue plasminogen activator, stmptokinase. or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622
126. ISIS-3. A randomised comparison of streplokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770
127. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-082
128. Vanderschueren SMF, Stassen JM, Collon D. On the inmmnogenicity of recombinant staphylokinaso in patients and animal models. Thromb Haemost 1904;72:297-301
129. Collen D, de Cock F, Stassen JM. Comparative immunogonicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993;87:996-1006
130. Holvoet P, et al. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates, Circulation 1993;87:1007-1016
131. Collen D, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibilor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1094;72:98-104
132. Collen D, et al. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokiuaso-type plasminogon activators. Circulation 1991;84:1216-1234
133. Kartchner MM, Wilcox WC. Thrombolysis of palmar and digital arterial thrombosis by intra-arterial thrombolysin. J Hand Surg [Am] 1976;1:67-74
134. Puckett CL, Misholy H, Reinisch JF, The effects of streptokinaso on ischemic flaps. J Hand Surg [Am] 1983;8:101-104
135. Krupski WC, Feldman RK, Rapp JH. Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: preliminary report. J Vasc Surg 1989;10:491-498
136. Fernandez Ortiz A, lang IK, Fuster V. Antiplatelet and antithrombin therapy. Coron Artery Dis 1994;5:297-305
137. Vaitkus PT. Indications for antithrombotic therapy after myocardial infarction. Heart Dis Stroke 1994;3:24-28
138. Fox KM, Mulcahy D, Purcell H. Unstable and stable angina. Eur Heart J 1993;14(Suppl F):15-17
139. Moran KT, Jewoll ER, Persson AV. The role of thrombolytic, therapy in surgical practice. Br J Surg 1989;76:298-304
140. Sherry S. Thrornbolytic therapy for noncoronary diseases. Ann Emerg Med 1991;20:396-404
141. Lawrence PF, Goodman GR. Thrombolytic therapy. Surg Clin North Am 1992;72:899-918
142. Didishoim P. The quest for thromboresistant materials. Semin Thromb Hemost 1989;15:240-243